Archives of Sexual Behavior

, Volume 27, Issue 5, pp 475–492 | Cite as

A Follow-Up Study for Estimating the Effectiveness of a Cross-Gender Hormone Substitution Therapy on Transsexual Patients

  • Kathrin Schlatterer
  • Alexander Yassouridis
  • Klaus Von Werder
  • Dorette Poland
  • Johannes Kemper
  • Gunter K. Stalla


This follow-up study was carried out to validate the effectiveness of cross-gender hormone therapy embedded in a multistep treatment concept for transsexual patients. This therapy described in detail by the authors elsewhere and presented briefly below provides cross-gender hormone substitution to obtain an assimilation of secondary sex characteristics to the desired sex as quickly as possible. Personal and social background data of 46 male-to-female (M-to-F) and 42 female-to-male (F-to-M) patients passing through different stages of the treatment concept were included. In the Endocrinological Outpatient Clinic of the Max-Planck-Institute/Munich the effectiveness of cross-gender hormone replacement therapy as well as frequency and distribution of side effects were examined by follow-up examination of endocrinological parameters. Cross-gender hormones were administered either parenterally or orally. Blood samples were collected routinely after 2 to 6 months depending on the duration of hormone substitution and complication rate. The incidence of hyperprolactinemia in estrogen-treated M-to-F transsexuals lies in the range of studies published before, whereas the number of patients developing galactorrhea is significantly lower in our patients. The incidence of thromboembolic events during the time of cross-gender hormone treatment in our patients is negligible. Changes in hematological parameters are observed under cross-gender hormone therapy. With the cross-gender hormone regimen performed by us it is possible to generate less side effects in the treatment of transsexual patients than described before.



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alexanian, R. (1969). Erythropoietin and erythropoiesis in anemic man following androgens. Blood 33: 564–572Google Scholar
  2. Asscheman, H., Gooren, L. J. G., Assies, J., Smits, J. P. H., and de Slegte, R. (1988). Prolactin levels and pituitary enlargement in hormone treated male-to-female transsexuals. Clin Endocrinol 28: 583–588.Google Scholar
  3. Asscheman, H., Gooren, L. J. G., and Eklund, P. L. E. (1989). Mortality and morbidity in transsexual patients with cross-gende r hormone treatment. Metabolism 38: 869–873.Google Scholar
  4. Biller, J., and Saver, J. (1995). Ischemic cerebrovascular disease and hormone therapy for infertility and transsexualism. Neurology 45: 1611–1613.Google Scholar
  5. Damewood, M. D., Bellantoni, J. J., Bachorik, P. S., Kinball, A. W. Jr., and Rock, J. A. (1989). Exogenous estrogen effect on lipid/lipoprotein cholesterol in transsexual males. J. Endocrinol Invest. 12: 449–454.Google Scholar
  6. de Gowin, R., Richard, L., Lavender, A. R., Forland, M., and Charleston, D. (1970). Erythropoietin and erythropoiesis in patients with chronic renal failure treated with hemodialysis and testosterone. Ann. Intern. Med. 72: 913–918.Google Scholar
  7. de Marinis, M., and Arnett, E. N. (1978). Cerebrovascular occlusion in a transsexual man taking me stranol. Arch. Intern. Med. 138: 1732–1733.Google Scholar
  8. Dixen, J. M., Maddever, H., van Maasdam, J., and Edwards, P. W. (1984). Psychosocial characteristics of applicants evaluated for surgical cross-gender re assignment. Arch. Sex. Behav. 13: 269–276.Google Scholar
  9. Fleming, M., Cohen, D., Salt, P., Jones, D., and Jenkins, S. (1981). A study of pre-and postsurgical transsexuals: MMPI characteristics. Arch. Sex. Behav. 10: 161–170.Google Scholar
  10. Fortin, C. L., Klein, T., Messmore, H. L., and O'Connell, J. B. (1984). Myocardial infarction and severe thromboembolic complications as seen in an estrogen-dependent transsexual. Arch. Intern. Med. 144: 1082–1083.Google Scholar
  11. Fried, W., Jonasson, O., and Lang, G. (1973). The hematological effect of androgen in uremic patients. Ann. Intern. Med. 79: 823–827.Google Scholar
  12. Futterweit, W. (1980). Endocrine management of the transsexual. N.Y. State J. Med. 80: 1260–1264.Google Scholar
  13. Glashan, R. W., and Robinson, M. R. G. (1981). Cardiovascular complications in the treatment of prostatic carcinoma. Br. J. Urol. 53: 624–627.Google Scholar
  14. Goh, H. H., Loke, D. F. M., and Ratnam, S. S. (1995). The impact of long-term testosterone replaceme nt therapy on lipid and lipoprotein profiles in women. Maturitas 21: 65–70.Google Scholar
  15. Goodwin, W. E., and Cummings, R. H. (1984). Squamous metaplasia of the verumontanum with obstruction due to hypertrophy: long-term effects of estrogen on the prostate in an aging male-to-female transsexual. J. Urol. 131: 553–554.Google Scholar
  16. Gooren, L. (1990). The endocrinology of trans sexualism: Review and commentary. Psychoneuroend ocrinology 15: 3–14.Google Scholar
  17. Gooren, L. J. G., van der Veen, E. A., and van Kessel, H. (1980). Modulation of prolactin secretion by gonadal steroids in men. In: MacLeod, R. M., and Scapagnini, U. (eds.), Central and Peripheral Regulation of Prolactin Function, Raven Press, New York, pp.373–375.Google Scholar
  18. Green, R. (1966). Mythological, historical, and cross-cultural aspects of transsexualism. In Benjamin H. The Transsexual Phenomenon. The Julian Press, New York.Google Scholar
  19. Hannaford, P. C., Croft, P. R., and Kay, C. R. (1994). Oral contraception and stroke. Stroke 25: 935–942.Google Scholar
  20. Hoenig, J., and Kenna, J. (1973). Epidemiological aspects of transsexualism. Psychiat. Clin. 6: 65–80.Google Scholar
  21. Kennedy, B. J., and Gilbertsen, S. (1957). Increased erythropoesis induced by androgenic hormone therapy. New. Engl. J. Med. 256: 719–726.Google Scholar
  22. Kockott, G., and Fahrner, E. M. (1988). Male-to-female and female-to-male transsexuals: A comparison. Arch. Sex. Behav. 17: 539–546.Google Scholar
  23. Kovacs, K., Stefaneanu, L., Ezzat, S., and Smyth, H. S. (1994). Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. Arch. Pathol. Lab. Med. 118: 562–565.Google Scholar
  24. Lehrman, K. L. (1976). Pulmonary embolism in a transsexual man taking diethlstilbestrol. J. Am. Med. Assoc. 235: 532–533.Google Scholar
  25. Meyer, W. J., Webb, A., and Stuart, C. A. (1986). Physical and hormonal evaluation of the transsexual patient. A longitudinal study. Arch. Sex. Behav. 15: 121–138.Google Scholar
  26. Pauly, I. (1965). Male psychosexual inversion: Transsexualism. Arch. Gen. Psychiat. 13: 172–181.Google Scholar
  27. Pauly, I. B. (1968). The current status of the sex change operation. J. Nerv. Ment. Dis. 147: 460–471.Google Scholar
  28. Pauly, I. B. (1974). Female transsexualism I and II. Arch. Sex. Behav. 3: 487–526.Google Scholar
  29. Pritchard, T. J., Pankowsky, D. A., Crowe, J. P., and Abdul-Karim, F. W. (1988). Breast cancer in a male-to-female transsexual. A case report. J. Am. Med. Assoc. 259: 2278–2280.Google Scholar
  30. Schlatterer, K., von Werder, K., and Stalla, G. K. (1996). Multistep treatment concept of transsexual patients. Exp. Clin. Endocrinol. (in press).Google Scholar
  31. Stadel, B. V. (1981). Oral contraceptives and cardiovascular disease. New Engl. J. Med. 305: 612–618, 672–677.Google Scholar
  32. Symmers, W. C. (1968). Carcinoma of the breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br. Med. J. 2: 83–85.Google Scholar
  33. Tsoi, W. F. (1990). Developmental profile of 200 male and 100 female transsexuals in Singapore. Arch. Sex. Behav. 19: 595–605.Google Scholar
  34. Tsoi, W. F. (1992). Male and female transsexuals: A comparison. Singapore Med. J. 33: 182–185.Google Scholar

Copyright information

© Plenum Publishing Corporation 1998

Authors and Affiliations

  • Kathrin Schlatterer
  • Alexander Yassouridis
  • Klaus Von Werder
  • Dorette Poland
  • Johannes Kemper
  • Gunter K. Stalla

There are no affiliations available

Personalised recommendations